The ATTENTION study is a randomized, double-blind, placebo-controlled, phase III trial that compares erlotinib with or without tivantinib in Asian patients with previously treated IIIB/IV non-squamous NSCLC harboring wild-type EGFR. Here, EGFR is linked to non-small cell lung carcinoma.